Pictet Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Pictet Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$72.8M	Sell	430,635 -172,008	-29%	-$25.5M	0.07%	266
2026 Q1	$78.9M	Sell	602,643 -174,291	-22%	-$23.1M	0.08%	243
2025 Q4	$110M	Buy	776,934 +83,488	+12%	+$12.1M	0.11%	205
2025 Q3	$97.3M	Sell	693,446 -2,676	-0.4%	-$363K	0.09%	222
2025 Q2	$87.5M	Buy	696,122 +308,548	+80%	+$35.4M	0.09%	224
2025 Q1	$43.1M	Sell	387,574 -223,545	-37%	-$28.3M	0.05%	336
2024 Q4	$83.4M	Sell	611,119 -231,078	-27%	-$28.6M	0.09%	228
2024 Q3	$97M	Sell	842,197 -29,127	-3%	-$3.99M	0.11%	201
2024 Q2	$120M	Sell	871,324 -210,125	-19%	-$28.8M	0.14%	173
2024 Q1	$149M	Sell	1,081,449 -131,864	-11%	-$18M	0.16%	164
2023 Q4	$160M	Buy	1,213,313 +169,863	+16%	+$19.6M	0.18%	147
2023 Q3	$117M	Buy	+1,043,450	New	+$110M	0.14%	176

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Pictet Asset Management's NBIX Position: Q2 2026 in Review

Pictet Asset Management reduced its Neurocrine Biosciences (NBIX) stake by 29% in Q2 2026, selling an estimated $25.5M and leaving 430,635 shares worth $72.8M. The position accounts for 0.07% of the portfolio, ranked #266.

Pictet Asset Management first reported a position in NBIX in Q3 2023 and has held it in 12 quarters since. The position peaked at $160M in Q4 2023. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Pictet Asset Management held 430,635 shares of Neurocrine Biosciences worth $72.8M as of Q2 2026.
Pictet Asset Management sold 172,008 Neurocrine Biosciences shares in Q2 2026, an estimated $25.5M.
Neurocrine Biosciences made up 0.07% of Pictet Asset Management's portfolio in Q2 2026, its #266 holding.
Pictet Asset Management first reported a position in Neurocrine Biosciences in Q3 2023 and has held it in 12 quarters since.
Pictet Asset Management's Neurocrine Biosciences position peaked at $160M in Q4 2023.
781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.